Product Description
Mechanisms of Action: PSMA Modulator
Novel Mechanism: Yes
Modality: Diagnostic Agent
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Yunhe Pharmaceutical (Tianjin) Co., Ltd
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for INR-101](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
INR101-I/IIa-01 | P2 |
Recruiting |
Prostate Cancer |
2025-03-31 |
|
CTR20241842 | P1 |
Unknown |
Prostate Cancer |
None |